Home/Filings/4/0000950117-09-000227
4//SEC Filing

Hamelin Paul 4

Accession 0000950117-09-000227

CIK 0000722104other

Filed

Feb 18, 7:00 PM ET

Accepted

Feb 19, 5:19 PM ET

Size

11.4 KB

Accession

0000950117-09-000227

Insider Transaction Report

Form 4
Period: 2008-12-13
Hamelin Paul
President
Transactions
  • Sale

    Common Stock, $.01 par value per share

    2009-12-17$5.77/sh1,777$10,25297,034 total
  • Award

    Common Stock, $.01 par value per share

    2009-12-13$5.94/sh+50,000$297,00098,811 total
  • Exercise/Conversion

    Option to Purchase Common Stock, $.01 par value

    2009-02-19$8.27/sh40,000$330,800140,000 total
    Exercise: $8.27Exp: 2019-02-19Common Stock, $.01 par value per share (40,000 underlying)
  • Exercise/Conversion

    Option to Purchase Common Stock, $.01 par value

    2009-02-19$5.27/sh100,000$527,000100,000 total
    Exercise: $5.27From: 2010-02-19Exp: 2019-02-19Common Stock, $.01 par value per share (100,000 underlying)
Footnotes (3)
  • [F1]The right to receive these shares is pursuant to a restricted stock grant and such shares issue and vest as to 33.3% on each of 2/13/10, 2/13/10 and 2/13/11, provided the grantee remains employed by the Company on these dates.
  • [F2]These shares were sold automatically pursuant to a binding contract under Rule 10b5-1 of the Securities Exchange Act of 1934, to cover tax withholding obligations in connection with the vesting of restricted stock granted on February 15, 2007.
  • [F3]These options will become exercisable as to 25% on each of 2/19/10, 2/19/11, 2/19/12 and 2/19/13, provided the optionee remains employed by the Company on these dates.

Issuer

SAVIENT PHARMACEUTICALS INC

CIK 0000722104

Entity typeother

Related Parties

1
  • filerCIK 0001364190

Filing Metadata

Form type
4
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 5:19 PM ET
Size
11.4 KB